Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

BioMarin says gene therapy hold will endure as FDA questions cancer risk
BioMarin says gene therapy hold will endure as FDA questions cancer risk
BioMarin Pharmaceutical will need to run additional preclinical studies to assess the "theoretical" cancer risk of a rare disease gene therapy it's developing, information the Food and Drug Adminis...
Merck and Ridgeback Statement on Clinical Trial of Hetero’s Generic Molnupiravir
Merck and Ridgeback Statement on Clinical Trial of Hetero’s Generic Molnupiravir
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today issued the following statement regarding the clinical trial of Hetero’s generic molnupiravir.  ...
How an OTC cough med could serve as a steppingstone for creating heart rhythm drugs
How an OTC cough med could serve as a steppingstone for creating heart rhythm drugs

The cough medicine dextromethorphan has been shown to treat inherited heart arrhythmia disorders in mouse models and human cells. 

FDA approves treatment for anemia in adults with rare inherited disorderves treatment for anemia in adults with rare inherited disorder
FDA approves treatment for anemia in adults with rare inherited disorderves treatment for anemia in adults with rare inherited disorder
FDA has approved Pyrukynd (mitapivat) tablets  to treat hemolytic anemia (a disorder in which red blood cells are destroyed faster than they can be made) in adults with pyruvate kinase (PK) d...
ChemDiv’s Triazoles Library contains 4000 compounds
ChemDiv’s Triazoles Library contains 4000 compounds
The triazole moiety is present in a large number of FDA-approved drugs, drug candidates, and lead compounds. This heterocycle, for example, is considered as a privileged structure of antifungal com...
A global view on fatty liver and diabetes helps to fight other non-communicable diseases and COVID-19
A global view on fatty liver and diabetes helps to fight other non-communicable diseases and COVID-19
Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, similar to the non-communicable diseases cancer, obesity, cardiovascular disease and diabetes. ...
Covid-19 pandemic: Six African countries to receive mRNA vaccine technology
Covid-19 pandemic: Six African countries to receive mRNA vaccine technology
The first African countries selected to receive the technology necessary to produce mRNA vaccines against COVID-19 are Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia, a summit meeting of ...
Teva Suffers Another Blow in ‘Skinny Labeling’ Case Against GSK
Teva Suffers Another Blow in ‘Skinny Labeling’ Case Against GSK
A federal appeals court has upheld a decision ordering Teva Pharmaceuticals to pay $235.5 million to GlaxoSmithKline for infringing on the latter’s patent for its congestive heart failure drug Co...
FDA Grants Priority Review to BMS’ Supplemental BLA for Breyanzi
FDA Grants Priority Review to BMS’ Supplemental BLA for Breyanzi
The FDA has granted a Priority Review to Bristol Myers Squibb’s application for Breyanzi (lisocabtagene maraleucel) as a second-line treatment for adults with relapsed or refractory B-cell lymph...
Inside the tactical tug of war over the controversial Alzheimer's drug
Inside the tactical tug of war over the controversial Alzheimer's drug
The drug industry, patient advocates and congressional Republicans have all attacked federal officials' decision to decline routine Medicare coverage for a controversial Alzheimer's drug.  ...
Moderna’s commercial network grows
Moderna’s commercial network grows

Vaccine pioneers expand presence throughout Europe with a view to leveraging technology.

FDA Halts Legend Biotech’s CAR-T Cell Therapy Trial After Just One Patient is Dosed
FDA Halts Legend Biotech’s CAR-T Cell Therapy Trial After Just One Patient is Dosed
After dosing just one patient in a phase 1 trial, the FDA put a clinical hold on Legend Biotech’s early-stage CAR-T cell therapy, LB1901, which targets malignant CD4+ T-cells. ...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand